<DOC>
	<DOCNO>NCT00015756</DOCNO>
	<brief_summary>This study examine relationship bacterial product lung infection cystic fibrosis disease severity . It examine plasma lung tissue cystic fibrosis patient . Patients cystic fibrosis certain genetic characteristic , 9 65 year age cystic fibrosis patient undergo lung transplantation INOVA Fairfax Hospital Fairfax , Virginia , may eligible study . Patients undergo apheresis may ask provide additional 100 cc ( 7 tablespoon ) blood research look bacterial product . Lung specimens participate transplant patient collect INOVA Fairfax Hospital . Patients participate apheresis portion study admit NIH Clinical Center 2 3 day . Apheresis procedure collect large quantity specific blood component . For study , plasma-the liquid part blood-will collect . For procedure , whole blood collect needle arm vein , similar donate blood . The blood separate component centrifugation ( spin ) , plasma white cell extract collected bag , red cell return body , either needle another needle arm . During hospital stay , patient may also ask participate cystic fibrosis study involve blood test , echocardiogram ( ultrasound test heart ) , urine pregnancy test , pulmonary function ( breathe ) test .</brief_summary>
	<brief_title>Tissue Collection From People With Cystic Fibrosis</brief_title>
	<detailed_description>Lungs individual cystic fibrosis ( CF ) frequently colonize number bacterial pathogen . One common organism Pseudomonas aeruginosa . Previous study show presence type III-secretion pathway within P. aeruginosa , implicate cytotoxin virulence factor organism . To evaluate effect cytotoxin lung cell , would like collect plasma tissue individual CF . Because large quantity plasma safely obtain simple phlebotomy require , apheresis procedure perform Clinical Center Apheresis Unit use . To obtain lung cell patient CF infect P. aeruginosa , tissue explanted lung collect collaboration INOVA Fairfax Hospital . We intend look expression type- III proteins P. aeruginosa measure immune response component type- III pathway presence lung cell .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>INCLUSION CRITERIA : Individuals CF identify mutation cystic fibrosis transmembrance regulator ( CFTR ) ( i.e. , known variant CFTR gene , change F508 allele ) age 18 year 65 year include apheresis portion study . Patients genotyped another protocol . Patients must colonize history colonization P. aeruginosa . Patients may culture organism ( e.g. , Burkholderia cepacia ) . All patient undergo lung transplantation include study . Based data various CF registry , mean age patient receive transplant 26 year range 5 59 year . Any patient age 9 CF undergoing transplantation eligible explantation portion study . EXCLUSION CRITERIA : There exclusion criterion subject transplant portion study . Patients CF exclude apheresis portion study le 18 year , weigh less 40kg , demonstrate : 1 . Cardiovascular instability ; 2 . Severe anemia ( hematocrit le 28 percent , hemoglobin le than10gm/ml ) ; 3 . Thrombocytopenia ( Platelets le 50,000 ) ; 4 . Inadequate venous access upper extremity ( No central venous catheter use ) ; 5 . Severe coagulation disorder ; 6 . Positive serology hepatitis B , C , HIV ; 7 . Pregnancy ; 8 . Pulmonary hypertension ; 9 . Respiratory exacerbation require intravenous antibiotic ; 10 . Any condition physician Apheresis Unit staff considers contraindication procedure . Individuals unable provide adequate consent/assent exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 21, 2008</verification_date>
	<keyword>Apheresis</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Type III Secretion Pathway</keyword>
	<keyword>Exotoxins</keyword>
	<keyword>Pseudomonas Aeruginosa</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>CF</keyword>
</DOC>